Sure, it's a growth-by-acquisition story, but at least they are acquiring into an industry with structural growth tailwinds.

Net Profit After Tax lower: $5,933Mill (16.2%)

Net Debt/ Equity is ok so has liquidity here .. We looking for the these acquisitions to be integrated, sustainable.

https://hotcopper.com.au/threads/ann-appendix-4e-fy25-financial-statements.8731195/

Unfilled Contracted Revenue Recent large contract wins in North America and growth in most other regions across the group have contributed to the continued growth of Austco’s Unfilled Contracted Revenue (UCR). Our UCR book now stands at $53.8 million at 13 August 2025. This includes a net $6.3 million from the recently acquired G&S, being their UCR less orders they had open with Austco NZ. 

Cash and Working Capital Position Cash on hand was $14.5m at 30 June 2025, up from $13.6 million at June 2024. Cash generated from operating activities of $13.48 million reflected underlying profitability and allowed for the investment into further businesses (G&S acquired in May 2025) without the need for debt or raising capital. Despite working capital increasing as a result of acquiring G&S, the Group is well placed to fund future contingent consideration obligations without the need for liquidity events, if it chooses to do so. 

AHC closed lower while the XJO 8,395 -0.40% also lower

Return (inc div)   1yr: 71.43%   3yr: 50.53% pa   5yr: 38.36% pa

Updated calculation 12th Aug. 2025

My valuation Calculation from 3 weeks ago Just to clarify the projected Share Price $0.504 ( say an eps growth 12% pa)

The Intrinsic Value shown in your Google Sheet ($0.38) is the estimated true worth of AHC’s shares based on your forecasted financials and valuation assumptions.

https://hotcopper.com.au/threads/ann-austco-healthcare-trading-update-and-guidance-upgrade.8677109/

think, AHC should be able to scale up the model: support for over 5,000 healthcare facilities worldwide.

Unfilled Contracted Revenue Unfilled contracted revenue currently stands at $55.8 million, up from $50.2 million reported in February 2025. The increase reflects the addition of G&S Technologies to the Group since the last update, as well as continued strong operational performance, including a record revenue delivery of $13.2 million (unaudited) in June 2025. Amentco Earn-Out Adjustment The earn-out period for the acquisition of Amentco concluded on 30 June 2025.

Based on the strong performance of Amentco, Austco now expects a final earn-out payment of approximately $8.4 million, exceeding the previously accrued amount of $5.9 million. Under accounting standards, the incremental $2.5 million must be expensed through the income statement rather than adjusted through goodwill. While this will reduce statutory net profit as at 30 June 2025, it has no impact on EBITDA.

Austco retains the option to settle up to 50% of the $8.4 million earn-out in Austco shares, with the balance in cash. A decision on the option to settle is expected following on or around the release of the audited Full Year Results.

CEO Commentary Commenting on the performance, Clayton Astles, CEO of Austco, said: “FY25 was a transformative year for Austco. We delivered strong double-digit growth, successfully integrated acquisitions, and executed our strategy with discipline. Our ability to fund acquisitions through operating cashflow while maintaining a strong balance sheet reflects the resilience and scalability of our business model. With robust contracted revenue and momentum across key markets, we enter FY26 with confidence.”

The Company expects to release its audited Full Year Results and Appendix 4E on 26 August 2025. Authorised for release by the Board of Austco Healthcare Limited.

Austco Healthcare Limited (AHC) is an international provider of healthcare communication solutions, including nurse call systems, mobile communications, and clinical workflow management. Founded in Australia, the company has expanded its presence globally, with subsidiaries in six countries and support for over 5,000 healthcare facilities worldwide. Austco's competitive advantage lies in its advanced IP-based nurse call systems, 

Chart shows a great trend here:

Return (inc div)   1yr: 81.40%   3yr: 54.60% pa   5yr: 40.97% pa

Can AHC announcements be found at https://hotcopper.com.au/asx/ahc/?keywords=AHC ? 1/ For example 14th May 2025 - Toronto Western Hostpital

Yes — HotCopper does list AHC’s ASX announcements, including the one from 14 May 2025 regarding the Toronto Western Hospital contract.

Example: AHC — Toronto Western Hospital (14 May 2025)

• On HotCopper, the thread titled “AHC Ann: Secures $2.1M contract at Toronto Western Hospital” reflects the official ASX announcement posted on that date HotCopper.
• In addition, the Announcements page under AHC on HotCopper compiles the company’s recent ASX disclosures, including that same contract announcement, along with many others like acquisitions, results, and trading updates HotCopper+1.

Summary

Yes, you can find AHC company announcements on the HotCopper site — including the 14 May 2025 announcement about the Toronto Western Hospital contract. It’s a convenient repository that mirrors, in near real-time, the ASX releases.

The CHAT GPT missed - the announcements so I conclude Chat GPT is has limited asx knowledge here:

The likely outlook for AHC - no company-issued forward guidance!

I couldn’t find any company-issued, forward-looking guidance for FY 2026 from Austco Healthcare (ASX: AHC)—no specific projections for EPS growth, revenue targets, or contract estimates are disclosed publicly at this time.

FY 2025 Guidance (Latest Available)

Austco has provided detailed FY 2025 guidance in its ASX announcement dated 23 July 2025:

• Revenue: forecasted at AUD 80–82 million, up 37–41% from FY 2024’s AUD 58.2 million investorpa.comaustcohealthcare.com.
• EBITDA: projected between AUD 12.5–13.5 million, marking a 54–67% increase over FY 2024’s AUD 8.1 million investorpa.comaustcohealthcare.com.
• Contracted (unfulfilled) revenue pipeline: currently stands at AUD 55.8 million, up from AUD 50.2 million in early 2025 investorpa.comaustcohealthcare.com.

These figures provide insight into Austco’s near-term expectations but stop short of detailing FY 2026.

What About FY 2026?

• There is no published or analyst-provided guidance on EPS, revenue, or contracts specifically for FY 2026.
• Analyst forecasts, such as those from Simply Wall St, offer general multi-year growth projections, but they reflect aggregated expectations—not company-issued forward guidance:
• EPS growth: ~18.85% per annum
• Earnings growth: ~21.4% per annum
• Revenue growth: ~14.3% per annum Simply Wall St

Summary

YearEPS GrowthRevenue GrowthContracts (Pipeline)FY 2025Not disclosedGuided: +37–41% (AUD 80–82 m)Pipeline: AUD 55.8 mFY 2026———Analyst Avg.~18.9% p.a.~14.3% p.a. (multi-year)—

Next Steps

If you're seeking FY 2026 guidance, you may want to monitor these channels:

• Upcoming Annual Results (Full Year FY 25) due 26 August 2025, when Austco may release fresh guidance or commentary austcohealthcare.com.
• Investor presentations or ASX releases later this year—especially the FY 2025 results—often include forward commentary on the next fiscal year.

@Bear77 , @DrPete I hope this answers some questions

I've just posted a valuation for Austco. Overall it looks strong. But I'm relatively new to this company. So I have a few questions for the Austco old-timers and wise folks.

Since June 2024 the Return on equity is: 20.28%, Net profit margin: 12%, :

1/ Why did revenue start to grow in 22/23 after many years of stagnating?

2/ Who are Austco's main competitors?

3/ Who is John Bennetts and why does he own 16%?

4/ Who is Robert Grey and why has he been aggressively offloading shares?

5/ Is there a reason Austco uses the language "revenue from customers" rather than just "revenue"?

6/ How comfortable are you with the strategy of acquiring resellers, given the resellers aren't entirely

7/ focused on reselling just Austco but also have other unaligned sources of revenue and profit?

8/ is the 'Net profit Margin' at 12% because of a contract win?

1. Why did revenue start to grow in FY22–23 after years of stagnation?

Austco’s revenue took off thanks to two main factors:

• Organic growth—especially in North America and Asia—grew revenue by about 17% or ~AUD 7 million.
• Acquisitions—Teknocorp (Nov 2023) added AUD 6.5 million and Amentco (May 2024) added AUD 2.7 million. Combined, that delivered a 39% jump in "revenue from customers" over FY23 to FY24.austcohealthcare.com+1Listcorp

2. Who are Austco’s main competitors?

Sources list a range of competitors depending on perspective:

• Craft.co: Ascott Sales Integration, Rethink Medical, MOMI Brands, and RudolfCraft.co
• CB Insights: 9Solutions, Schweighofer Fiber, MatchMD, West-Com Nurse Call Systems, plus othersCB Insights
• Tracxn: Names athenahealth, CareCloud, and Notable among the top rivalsTracxn+1
• For global scale, Austco’s market share in healthcare comms is relatively small—under 1%, compared to giants like Cerner, McKesson, and athenahealthEnlyft+1

3. Who is John Bennetts and why does he own ~16%?

According to MarketScreener, John Bennetts holds ~15.63% of Austco’s shares, making him the largest individual shareholderMarketScreener. I couldn’t find more detail on his background or motivations for his stake.

4. Who is Robert Grey and why has he been offloading shares?

Robert Edward Grey is Austco’s long-time founder (founded in 1986) and has held executive and board roles. As of a 2024 update, he owns ~14.51% and is no longer in an executive roleMarketScreenerMarketScreener UAE EmiratesTracxn. The share reductions may reflect typical founder portfolio diversification or liquidity needs, though no explicit rationale was found.

5. Why does Austco use “revenue from customers” rather than just “revenue”?

This phrasing likely distinguishes recognized sales from existing contracts still to be fulfilled (“unfilled contracted orders”)—which stood at a record AUD 50 million as of FY24austcohealthcare.com+1. It clarifies actual billing versus future revenue potential.

6. What about the strategy of acquiring resellers who also sell other products?

Austco’s strategy appears to intentionally target resellers with established regional reach. Acquisitions like Teknocorp and Amentco not only added revenue but also embedded Austco’s offerings deeper in their networks—allowing revenue synergies while maintaining reseller autonomyListcorp+1austcohealthcare.com. While reseller loyalty might not be exclusive, Austco seems focused on aligning them through integration and software upsell opportunities.

7. Is the 12% net profit margin due to a specific contract win?

The net profit margin of roughly 12% in FY24 was up from ~5.4% in FY23—reflecting a strong combination of organic growth, M&A gains, operating leverage, and tax benefits from recognizing previously unrecognized tax lossesYahoo Financeaustcohealthcare.comListcorp. There’s no clear indication it hinges on a single contract.

Summary Table

QuestionSummary1. Revenue growthOrganic markets + two acquisitions2. CompetitorsIdentified across Craft, CB Insights, Tracxn; includes both med-tech startups & large EMR players3. John BennettsLargest shareholder (~15.6%), little else publicly known4. Robert GreyFounder, former director; now holds ~14.5%, likely managing personal stake5. “Revenue from customers” termDifferentiates recognized income from future contract pipeline6. Reseller acquisition strategyExtends reach and integration without demanding exclusivity7. Margin improvementDriven by scale gains, deal integration, and tax accounting — not a single contract win

Disc: S.M